在中国广泛期小细胞肺癌一线化疗中加入Serplulimab的成本效益分析数据集

数据集获取（Figshare）

• 源站标题：Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
• DOI：10.6084/m9.figshare.24542478.v1
• 发布日期：2023-11-10
• 文件数：2 个
• 文件总体积：13.18 MB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-effectiveness_of_adding_serplulimab_to_first-line_chemotherapy_for_extensive-stage_small-cell_lung_cancer_in_China/24542478

命令行下载

curl -L -o "ierp_a_2281606_sm7918.docx" "https://ndownloader.figshare.com/files/43108236"
curl -L -o "ierp_a_2281606_sm7913.docx" "https://ndownloader.figshare.com/files/43108239"

文件清单

• ierp_a_2281606_sm7918.docx（28.29 KB）
• ierp_a_2281606_sm7913.docx（13.15 MB）

文件总体积 13.18 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

The aim of the current study was to evaluate the cost-effectiveness of serplulimab plus chemotherapy compared chemotherapy alone as first-line strategy for patients with ES-SCLC in China.
A decision-analytic model that based on the Chinese health-care system perspective was conducted to evaluate the economic benefits for the two competing first-line treatment. The clinical survival and safety data were obtained from the ASTRUM-005 trial, cost and utility values were gathered from the local charges and previously published study. Both cost and utility values were discounted at an annual rate of 5%. Sensitivity analyses and subgroup analyses were performed to examine the robustness of the model results.
Serplulimab plus chemotherapy could bring additional 0.25 QALYs with the marginal cost of $37,569.32, resulting in an ICER of $147,908.74 per additional QALY gained. Sensitivity analyses confirmed that model results were robust. Subgroup analyses revealed that adding serplulimab to first-line chemotherapy were unlikely to be the cost-effective option for all subgroup patients.
Serplulimab plus chemotherapy was unlikely to be the cost-effective first-line strategy compared with chemotherapy alone for patients with ES-SCLC in China. Reduced the price of serplulimab could increase its cost-effective.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.24542478.v1（source: https://tandf.figshare.com/articles/dataset/Cost-effectiveness_of_adding_serplulimab_to_first-line_chemotherapy_for_extensive-stage_small-cell_lung_cancer_in_China/24542478）。